 scPharma is a small-cap biotech with a cardiology product, Furoscix, that was approved last October, expected to launch in 1Q 2023. We believe Furoscix is derisked as furosemide loop diuretics is the current standard of care, and the value proposition of SC dosage over IV is clear. 